GW Pharmaceuticals PLC Director Stock Trading Plan (7917N)
October 28 2016 - 11:58AM
UK Regulatory
TIDMGWP
RNS Number : 7917N
GW Pharmaceuticals PLC
28 October 2016
Director Stock Trading Plan
London, UK; 28 October 2016: GW Pharmaceuticals plc (Nasdaq:
GWPH, AIM: "GWP," "GW," "the Company" or "the Group"), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, has today been notified that Dr Geoffrey Guy,
Chairman of the Board, has established a personal stock trading
plan in accordance both with the guidelines established by Rule
10b5-1 under the U.S. Securities Exchange Act of 1934, as amended,
and the EU Market Abuse Regulation, as well as the Company's
policies with respect to insider sales.
Rule 10b5-1 plans permit directors, officers and other company
insiders to adopt, at times when they are not in possession of
material, non-public information, written plans for trading
securities in a non-discretionary, pre-scheduled manner in the
future. These pre-planned trades can then be executed at a later
date, as spelled out in the plan, without further action by the
director, officer or other company insider and without regard to
any subsequent non-public information the individual might have
received.
Dr Guy's plan provides for the exercise and sale of options over
up to 440,388 Ordinary 0.1p Shares (equivalent to 36,699 American
Depository Shares), between 9 December 2016 and 1 April 2017.
Following exercise of these options, Dr Guy will continue to
hold 952,034 options over Ordinary Shares (equivalent to 79,336
ADSs) and will continue to be the beneficial owner of an additional
12,847,852 Ordinary Shares (equivalent to 1,070,654 ADSs).
The transactions under the plan will be disclosed publicly
through Form 144 and Form 4 filings as required by the U.S.
Securities and Exchange Commission, and by announcement through a
Regulatory Information Service, as required by the EU Market Abuse
Regulation.
For further information, please contact:
GW Pharmaceuticals PLC +44 (0)1980 557 000
Adam George, Company Secretary
Peel Hunt LLP (Nominated Adviser)
James Steel/Oliver Jackson +44 (0) 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEVLFLQBFEFBD
(END) Dow Jones Newswires
October 28, 2016 11:58 ET (15:58 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Dec 2023 to Dec 2024